Clinical trial
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory…
NCT00096837 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00096837 |
|---|---|
| Title | A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma |
| Official title | An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium Injection |
| Enrollment | 25 |
| First posted | Nov 17, 2004 |
| Last update posted | Jun 8, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: